Abstract
Background: Antimicrobial peptides play an important role in the innate immune system. Possessing broad-spectrum antibacterial activity, antimicrobial peptides can quickly treat and kill various targets, including gram-negative bacteria, gram-positive bacteria, fungi, and tumor cells.
Objective: An overview of the state of play with regard to the research trend of antimicrobial peptides in recent years and the situation of targeting tumor cells, and to make statistical analysis of the patents related to anticancer peptides published in recent years, is important both from toxicological and medical tumor therapy point of view.
Methods: Based on the Science Citation Index Expanded version, the Derwent Innovation Index and Innography as data sources, the relevant literature and patents concerning antimicrobial peptides and anticancer peptides were analyzed through the Thomson Data Analyzer. Results of toxicologic and pharmacologic studies that brought to the development of patents for methods to novel tumor drugs were analyzed and sub-divided according to the specific synthesis of anticancer peptides.
Results: The literature and patent search data show that the research and development of global antimicrobial peptides and anticancer peptides has been in an incremental mode. Growing patent evidence indicate that bioinformatics technology is a valuable strategy to modify, synthesize or recombine existing antimicrobial peptides to obtain tumor drugs with high activity, low toxicity and multiple targets.
Conclusion: These findings may have important clinical implications for cancer treatment, especially in patients with conditions that are not currently treatable by other drugs, or that are resistant to existing cancer drugs.
Keywords: Anticancer peptides, antimicrobial peptides, anti-tumor, bibliometrics, biological activity, patent analysis.
[1]
Tehrani FA, Modaresifar K, Azizian S, Niknejad H. Induction of antimicrobial peptides secretion by IL-1beta enhances human amniotic membrane for regenerative medicine. Sci Rep 2017; 7(1): 1-7.
[2]
Wang CG, Yao WN, Zhang B, Hua J, Liang D, Wang HS. Lung cancer and matrix metalloproteinases inhibitors of polyphenols from Selaginella tamariscina with suppression activity of migration. Bioorg Med Chem Lett 2018; 28(14): 2413-7.
[3]
Gaspar D, Veig AS, Castanho MA. From antimicrobial to anticancer peptides. A review. Front Microbiol 2013; 4: 1-16.
[4]
Li Y, Shan Z, Yang B, Yang D, Men C, Cui Y, et al. Cathelicidin LL37 promotes epithelial and smooth-muscle-Like differentiation of adipose-derived stem cells through the Wnt/beta-Catenin and NF-kappaB pathways. Biochemistry (Mosc) 2017; 82(11): 1336-45.
[5]
Karapetyan AV, Klyachkin YM, Selim S, Sunkara M, Ziada KM, Cohen DA, et al. Bioactive lipids and cationic antimicrobial peptides as new potential regulators for trafficking of bone marrow-derived stem cells in patients with acute myocardial infarction. Stem Cells Dev 2013; 22(11): 1645-56.
[6]
Souza Cândido E, Silva Cardoso MH, Sousa DA, Viana JC, Oliveira-Júnior NG, Miranda V, et al. The use of versatile plant antimicrobial peptides in agribusiness and human health. Peptides 2014; 55: 65-78.
[7]
Alabdul Magid A. Voutquenne-Nazabadioko, Renimel I, Harakat D, Moretti C, Lavaud C, et al. Triterpenoid saponins from the stem bark of Caryocar villosum. Phytochemistry 2006; 67(19): 2096-102.
[8]
Gao H, Wang Z. Triterpenoid saponins and phenylethanoid glycosides from stem of Akebia trifoliata var. Australis. Phytochemistry 2006; 67(24): 2697-705.
[9]
Jiang D, Shi SP, Cao JJ, Gao QP, Tu PF. Triterpene saponins from the fruits of Akebia quinata. Bio Sys Ecol 2008; 36(8): 138-41.
[10]
Su X, Kong KF, Tsang JS. Transports of acetate and haloacetate in Burkholderia species MBA4 are operated by distinct systems. BMC Microbiol 2012; 12: 1-19.
[11]
Buscaill P, Rivas S. Transcriptional control of plant defence responses. Curr Opin Plant Biol 2014; 20: 35-46.
[12]
Taveira GB, Carvalho AO, Rodrigues R, Trindade FG, Da Cunha M, Gomes VM. Thionin-like peptide from Capsicum annuum fruits: Mechanism of action and synergism with fluconazole against Candida species. BMC Microbiol 2016; 16: 1-30.
[13]
McGovern DP, Astle AT, Clavin SL, Newell FN. Task-specific transfer of perceptual learning across sensory modalities. Curr Biol 2016; 26(1): R20-1.
[14]
Messina CS, Weiher H, Schmidt-Wolf IG. Targeting prostate cancer with a combination of WNT inhibitors and a bi-functional peptide. Anticancer Res 2017; 37(2): 555-9.
[15]
Huertas MNJ, Vargas CY, Gómez CAK, Hernández E, Leal CAL, Melo DJM, et al. Synthetic peptides derived from bovine lactoferricin exhibit antimicrobial activity against E. coli ATCC 11775, S. maltophilia ATCC 13636 and S. enteritidis ATCC 13076. Molecules 2017; 22(3): 1-10.
[16]
Fuente-Nunez C, Cardoso MH, Candido ES, Franco OL, Hancock RE. Synthetic antibiofilm peptides. Biochim Biophys Acta 2016; 1858: 1061-9.
[17]
Chen L, Zhu Y, Yang D, Zou R, Wu J, Tian H. Synthesis and antibacterial activities of antibacterial peptides with a spiropyran fluorescence probe. Sci Rep 2014; 4: 1-20.
[18]
Rudilla H, Fusté E, Cajal Y, Rabanal F, Vinuesa T, Viñas M. Synergistic antipseudomonal effects of synthetic peptide AMP38 and Carbapenems. Molecules 2016; 21(9): 1-12.
[22]
Zhang QH, Zhao R, Wang XJ, Blievins M. Methods and compositions for treating cancer and inflammatory diseases. US201414775643 (2016)
[23]
Lv FL, Li YC. A peptide drug or vaccine for the treatment of tumors caused by human papillomavirus type 18. ZL200710093235 (2008)
[24]
Lichter J, Harris JP, Dellamary LA, et al. Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders. US2013216609 (2013)
[26]
Cocks B, Spangenberg G. Method of treatment using antimicrobial composition. US2011209228 (2011)
[27]
Koob TJ. Cross-linked collagen with at least one bound antimicrobial agent for in vivo release of the agent. US9155799 (2015)
[28]
Lv FL, Mei H, Tian FF, Zhang Y, Li YC. A peptide drug for the treatment of diseases caused by highly pathogenic avian influenza virus. ZL2008102332148 (2009)
[29]
Liu F, Cao FH. Preparation of microspheres has prolonged release of medic-ament polypeptdique and prcede of preparation. CN201377403 (2013)
[30]
Liu YD, Zhang C, Su ZG. A tumor-targeted polypeptidedrug coupling derivative: A preparation method and its application. ZL2016108992930 (2018)
[31]
Wang L, Wang YJ, Liu YY, Li H, Guo LX, Liu ZH, et al. In vitro potential of Lycosin-I as an alternative antimicrobial drug for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2014; 58(11): 6999-7002.
[32]
Zhang Y, Zhou C, Chen DL. Preparation method of the albumin peptide combination and the action of inhibiting the proliferation of cancer cells thereof. US2018008678 (2017)
[33]
Wenschuh H, Schutkowski M, Zerweck J. Method for Determining the concentration of a peptide. US2013095514 (2013)
[34]
Guo Z, Li D, Peng H, Kang J, Jiang X, Xie X, et al. Specific hepatic stellate cell-penetrating peptide targeted delivery of a KLA peptide reduces collagen accumulation by inducing apoptosis. J Drug Target 2017; 25(8): 715-23.
[35]
Almaaytah A, Ajingi Y, Abualhaijaa A, Tarazi S, Alshar’i N, Al-Balas Q. Peptide consensus sequence determination for the enhancement of the antimicrobial activity and selectivity of antimicrobial peptides. Infect Drug Resist 2017; 10: 1-17.
[36]
Veltri D, Kamath U, Shehu A. Improving recognition of antimicrobial peptides and target selectivity through machine learning and genetic programming. IEEE/ACM Trans Comput Biol Bioinform 2017; 14(2): 300-13.
[37]
Veldhuizen EA, Scheenstra MR, Tjeerdsma-van Bokhoven JLM, Coorens M, Schneider VAF, Bikker FJ. In vitro potential of Lycosin-I as an alternative antimicrobial drug for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother 2017; 24(7): 609-16.
[40]
Huertas NJ, Monroy ZJR, Medina RF, Castañeda JEG. Castaneda, Antimicrobial activity of truncated and polyvalent peptides derived from the FKCRRQWQWRMKKGLA sequence against Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923. Molecules 2017; 22(6): 1-11.
[41]
Yang N, Liu X, Teng D, Li Z, Wang X, Mao R, et al. Antibacterial and detoxifying activity of NZ17074 analogues with multi-layers of selective antimicrobial actions against Escherichia coli and Salmonella enteritidis. Sci Rep 2017; 7(1): 3392-46.
[42]
Faust JE, Yang PY, Huang HW. Action of antimicrobial peptides on bacterial and lipid membranes: A direct comparison. Biophys J 2017; 112(8): 1663-72.
[43]
Metelev M, Arseniev A, Bushin LB, Kuznedelov K, Artamonova TO, Kondratenko R, et al. Acinetodin and klebsidin, RNA polymerase targeting lasso peptides produced by human isolates of Acinetobacter gyllenbergii and Klebsiella pneumoniae. ACS Chem Biol 2017; 12(3): 814-24.
[44]
Bi P, Ramirez-Martinez A, Li H, Cannavino J, McAnally JR, Shelton JM, et al. Control of muscle formation by the fusogenic micropeptide myomixer. Science 2017; 356(6335): 323-7.
[45]
Guaní-Guerra E, Santos-Mendoza T, Lugo-Reyes SO, Terán LM. Antimicrobial peptides: General overview and clinical implications in human health and disease. Clin Immunol 2010; 135(1): 1-11.
[46]
Culp E, Wright GD. Bacterial proteases, untapped antimicrobial drug targets. J Antibiot (Tokyo) 2017; 70(4): 366-77.
[47]
Wu Y, Chen Z, L, Hou J, J, Li XX. Peptide drug chelate with tumor-guided therapy and its application. ZL2013102598265 (2014)
[48]
Ma XY, Lin NJ, Zheng WY, Li LF, Liu H. A proteincarrying system for enhancing polypeptide drugs escaping from intracellular body and its application. ZL2013101783574 (2013)
[49]
Hao LY, Li JY, Li Z, Kang Z, Wang SQ. A class of peptide drug Athycaltide and its use. ZL2017114183143 (2018)
[50]
Dias SA, Freire JM, Pérez-Peinado C, Domingues MM, Gaspar D, Vale N, et al. New potent membrane-targeting antibacterial peptides from viral capsid proteins. Front Microbiol 2017; 8: 1-27.
[51]
Kim JS, Joeng JH, Kim Y. Design, Characterization and antimicrobial activity of novel antimicrobial peptide derived from bovine lactophoricin. J Microbiol Biotechnol 2017; 27(4): 759-.
[52]
Subbiah V, Velcheti V, Tuch BB, Ebata K, Busaidy NL, Cabanillas ME, et al. Selective RET kinase inhibition for patients with RET-altered cancers. Ann Oncol 2018; 1-8.
[53]
Lewies A, Wentzel JF, Jacobs G, Du Plessis LH. The potential use of natural and structural analogues of antimicrobial peptides in the fight against neglected tropical diseases. Molecules 2015; 20(8): 15392-433.
[55]
Moronta J, Smaldini PL, Docena GH, Añón MC. Peptides of amaranth were targeted as containing sequences with potential anti-inflammatory properties. J Funct Foods 2016; 21: 463-73.
[56]
Merriman JA, Nemeth KA, Schlievert PM. Schlievert, Novel antimicrobial peptides that inhibit gram positive bacterial exotoxin synthesis. PLoS One 2014; 9(4): e95661-7.
[57]
Segatori VI, Cuello HA, Gulino CA, Alberto M, Venier C, Guthmann MD, et al. Antibody-dependent cell-mediated cytotoxicity induced by active immunotherapy based on racotumomab in non-small cell lung cancer patients. Cancer Immunol Immunother 2018; 67(8): 1285-96.
[58]
Fuller TA, Sebastianelli WJ, Cohen PH, Voigt R C. Wysk, R. Ex vivo antimicrobial devices and methods. US2017165384 (2017)
[60]
Zheng L, Xua Y, Lin X, Yuan Z, Liu M, Cao S, et al. Recent progress of marine polypeptides as anticancer agents. Recent Patents Anticancer Drug Discov 2018; 13(4): 445-54.
[61]
Williamson J. Atezolizumab in patients with metastatic NSCLC. Lancet Respir Med 2018; 6(8): 584.
[62]
Zhang Y, Chen D, He LR, Liu LJ. Arginine-rich peptide mixture, their application thereof in cervical cancer therapy, and a process for producing same. US2018009842 (2017)
[63]
Tagliabue A, Rappuoli R. Changing priorities in vaccinology: Antibiotic resistance moving to the top. Front Immunol 2018; 9: 1-28.
[64]
Liu L, Chen Q, Ruan C, Chen X, Zhang Y, He X, et al. Platinum-based nano-vectors engineered with immuno-modulating adjuvant for inhibiting tumor growth and promoting immunity. Theranostics 2018; 8(11): 2974-87.
[65]
Velcheti V, Madison R, Ali SM, Schrock AB. Schrock, WAC/RET: A novel RET oncogenic fusion variant in non-small cell lung carcinoma. J Thoracic Oncology 2018; 13(7): e122-3.
[66]
Chen S, Wang H, Li Z, You J, Wu QW, Zhao C, et al. Interaction of WBP2 with ER-alpha increases doxorubicin resistance of breast cancer cells by modulating MDR1 transcription. Br J Cancer 2018; 1: 182-92.
[67]
Guo H, Li F, Xu W, Chen J, Hou Y, Wang C, et al. Mucoadhesive cationic polypeptide nanogel with enhanced penetration for efficient intravesical chemotherapy of bladder cancer. Adv Sci (Weinh) 2018; 5(6): 1-19.
[68]
Anaya-Ruiz M, Bandala C, Martinez-Morales P, Landeta G, Martinez-Contreras RD, Martinez-Montiel N, et al. Emerging drugs for the treatment of breast cancer brain metastasis: A review of patent literature. Recent Pat Anticancer Drug Discov 2018; 13(3): 348-59.
[69]
Ciupek A, Rechoum Y, Gu G, Gelsomino L, Beyer AR, Brusco L, et al. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERalpha-positive breast cancer. Breast Cancer Res Treat 2015; 154(2): 225-37.
[70]
Yu A, Wang Y, Bian Y, Chen L, Guo J, Shen W, et al. IL-1β promotes the nuclear translocation of S100A4 protein in gastric cancer cells MGC803 and the cell’s stem-like properties through PI3K pathway. J Cell Biochem 2018; 119(10): 8163-73.
[71]
Jain D, Supraja KS, Mohan A, Iyer VK. PD-L1 immunoexpression in matched biopsy and liquid based cytology samples of advanced stage non-small cell lung carcinomas. Cytopathology 2018; 29(6): 550-7.
[72]
Rupniewska E, Roy R, Mauri FA, Liu X, Kaliszczak M, Bellezza G, et al. Targeting autophagy sensitises lung cancer cells to Src family kinase inhibitors. Oncotarget 2018; 9(44): 27346-62.
[73]
Li Y, Du Y, Sun T, Xue H, Jin Z, Tian J. PD-1 blockade in combination with zoledronic acid to enhance the antitumor efficacy in the breast cancer mouse model. BMC Cancer 2018; 8(1): 1-12.
[74]
Hall CS, Karhade M, Laubacher BA, Kuerer HM, Krishnamurthy S, DeSnyder S, et al. Circulating tumor cells and recurrence after primary systemic therapy in stage III inflammatory breast cancer. J Natl Cancer Inst 2015; 107(11): 1-11.
[75]
Miguellillo B, Valenzuela B, Perisribera JE, Arturo SM, Juan JPR. Population pharmacokinetics of kahalalide F In advanced cancer patients. Cancer Chemo Pharmacol 2015; 7(62): 365-74.
[76]
Ratain MJ, Geary D, Undevia SD. First-in-human, Phase I study of elisidepsin(PM02734)administered as a 30min or as a 3hour in travenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs 2015; 33(4): 901-10.
[78]
Liu W, Ding R, Zhang Y, Mao C, Kang R, Meng J, et al. Transcriptome profiling analysis of differentially expressed mRNAs and lncRNAs in HepG2 cells treated with peptide 9R-P201. Biotechnology Lett 2017; 39(11): 1639-47.
[79]
Shepherd L, Ryom L, Law M, Petoumenos K, Hatleberg CI, d’Arminio Monforte A, et al. Cessation of cigarette smoking and the impact on cancer incidence in HIV-positive persons: The D: A: D study. Clin Infect Dis 2018. in press
[http://dx.doi.org/10.1093/cid/ciy508]
[http://dx.doi.org/10.1093/cid/ciy508]
[80]
Mauri D, Filis P, Tsali L, Zarkavelis G, Pentheroudakis G. Pentheroudakis, Role of chemotherapy in resectable liver metastases from colorectal cancer: Food for thought from pooled evidence. ESMO Open 2018; 3(4): e000367-7.
[81]
Feng C, Li X, Dong C, Zhang X, Zhang X, Gao Y. RGD-modified liposomes enhance efficiency of aclacinomycin A delivery: Evaluation of their effect in lung cancer. Drug Des Devel Ther 2015; 9: 4613-20.
[82]
Bi Z, Liu W, Ding R, Wu Y, Dou R, Zhang W, et al. A novel peptide, 9R-P201, strongly inhibits the viability, proliferation and migration of liver cancer HepG2 cells and induces apoptosis by down-regulation of FoxM1 expression. Eur J Pharmacol 2017; 796: 175-89.
[83]
Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, et al. CIMAvax-EGF, a therapeutic Non-Small Cell Lung Cancer vaccine. Expert Opin Biol Ther 2018; 18(7): 829-35.
[84]
Wang F, Shi JY, Jia B. Radionuclide labeled RGD polypeptide drugs and their preparation methods. ZL2009100777283 (2009)
[85]
Okamoto H, Taniyama Y, Sakurai T, Heishi T, Teshima J, Sato C, et al. Definitive chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-R) for advanced cervical esophageal cancer. Esophagus 2018; 15(4): 281-5.
[86]
Jin RU, Mills JC. Are gastric and esophageal metaplasia relatives? The case for Barrett’s stemming from SPEM. Dig Dis Sci 2018; 63(8): 2028-41.
[87]
Lordick F, Holscher AH, Haustermans K, Wittekind C. Multimodal treatment of esophageal cancer. Langenbecks Arch Surg 2013; 398: 177-87.
[88]
Kato H, Nakajima M. Treatments for esophageal cancer: A review. Gen Thor Cardiovas Surgery 2013; 61: 330-5.
[89]
Sonavane S, Watts J, Terry N, Singh SP. Expected and unexpected imaging features after oesophageal cancer treatment. Clinical Radiology 2014; 69(8): e358-66.
[91]
Hashem L, Swedrowska M, Vllasaliu D. Intestinal uptake and transport of albumin nanoparticles: Potential for oral delivery. Nanomedicine (London, England) 2018; 13(11): 1255-65.
[92]
Liu C, Chen C, Yang F, Li X, Cheng L, Song Y. Phytic acid improves intestinal mucosal barrier damage and reduces serum levels of proinflammatory cytokines in a 1,2-dimethylhydrazine-induced rat colorectal cancer model. Br J Nutr 2018; 120(2): 121-30.
[93]
Maynard MA, Ferretti R, Hilgendorf KI, Perret C, Whyte P, Lees JA. Bmi1 is required for tumorigenesis in a mouse model of intestinal cancer. Oncogene 2014; 33(28): 3742-7.
[94]
Ren SX, Cheng ASL, To KF, Tong JHM, Li MS, Shen J, et al.
Host immune defense peptide LL-37 activates caspase-independent
apoptosis and suppresses colon cancer. Cancer Res 2012; 72:
6512-23.
[95]
Wang W, Wan L, Wu S, Yang J, Zhou Y, Liu F, et al. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis. Cell Oncol (Dordr) 2018; 41(5): 495-504.
[96]
Wang J, Zhou Z, Zhang F, Xu H, Chen W, Jiang T. A novel nanocomposite based on fluorescent turn-on gold nanostars for near-infrared photothermal therapy and self-theranostic caspase-3 imaging of glioblastoma tumor cell. Colloids Surf B Biointerfaces 2018; 170: 303-11.
[97]
Verma MK, Goel R, Krishnadas N, Nemmani KVS. Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders. Expert Opin Ther Targets 2018; 22(7): 615-28.
[98]
Jahangiri B, Khalaj-Kondori M, Asadollahi E, Sadeghizadeh M. Cancer-associated fibroblasts enhance cell proliferation and metastasis of colorectal cancer SW480 cells by provoking long noncoding RNA UCA1. J Cell Commun Signal 2018. (in press)
[http://dx.doi.org/10.1007/s12079-018-0471-5]
[http://dx.doi.org/10.1007/s12079-018-0471-5]
[99]
Fosgerau K, Hoffmann T. Peptide therapeutics: Current status and future directions. Drug Discov Today 2015; 20(1): 122-8.
[100]
Qin ZD, Luo XF, Li ZZ. A new polypeptide that inhibits and kills many resistant bacteria. CN201610983077 (2016)
[102]
Qin ZD, Luo XF, He FL. A group of broad-spectrum antimicrobial peptides and their application. CN2016109838865 (2016)
[103]
Qin ZD, He FL, Ou YXP, et al. Antimicrobial peptides that inhibit and kill many resistant bacteria and their applicationsPCT109799 (2017).
[104]
Luo XF, Qin ZD, Li CJ. Antimicrobial peptides that inhibit and kill gram-positive and gram-negative bacteria. CN201610984016 (2016)
[105]
Kim JY, Han JH, Park G, Seo YW, Yun CW, Lee BC, et al. Necrosis-inducing peptide has the beneficial effect on killing tumor cells through neuropilin (NRP-1) targeting. Oncotarget 2016; 7(22): 32449-61.
[106]
Li Y, Xu N, Zhu W, Wang L, Liu B, Zhang J, et al. Nanoscale melittin zeolitic imidazolate frameworks for enhanced anticancer activity and mechanism analysis. ACS Appl Mater Interfaces 2018; 10(27): 22974-84.
[107]
Wu Y, Chang HM, Huang HF, Sheng JZ, Leung PC. Bone morphogenetic protein 2 regulates cell-cell communication by down-regulating connexin43 expression in luteinized human granulosa cells. Mol Hum Reprod 2017; 23(3): 155-65.
[108]
Thompson CM, Kirman CR, Proctor DM, Haws LC, Suh M, Hays SM, et al. A chronic oral reference dose for hexavalent chromium-induced intestinal cancer. J Appl Toxicol 2014; 34(5): 525-36.
[109]
Saleh N, Kleinau G, Heyder N, Clark T, Hildebrand PW, Scheerer P, et al. Binding, thermodynamics, and selectivity of a non-peptide antagonist to the melanocortin-4 receptor. Front Pharmacol 2018. (in press)
[http://dx.doi.org/10.3389/fphar.2018.00560]
[http://dx.doi.org/10.3389/fphar.2018.00560]
[110]
Qin ZD, Luo XF, Liu W. An antimicrobial peptide that inhibits and kills all kind of resistant bacteria. CN2016109839266 (2016)
[111]
Zhang JL, Jie JM, Nai XJ, Chen Y, Yue SH. Anticancer biological active peptide CB1a and application thereof. CN201810184631.1 (2018)
[112]
Ma WH, Wang J, Liu Y, Yang WD, Li GQ. Tumor vascular targeted anti-cancer skin NKL DOTA and preparation method thereof. CN201810242197. 8 (2018)
[114]
Wilson DT. Therapeutic compositions including mitochondrial fission inhibitor peptides, variants thereof, and methods of using the same. US20180042983 (2018)
[116]
Andrea M, Toni W, Anita W, Oliver S, Jens F, Harpreet S. Peptides and combination of peptides as targets or active ingredients for use in immunotherapy against AML and other cancers. US20170290897 (2017)
[117]
Andrea M, Toni W, Helen H, Oliver S, Jens F, Harpreet S. Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers. US20170002055 . (2017)
[118]
Chen DL, Zhang Y, He LR, Liu L. Arginine-rich peptide mixture, their application thereof in cervical cancer therapy, and a process for producing same. US20180009842 . (2018)
[119]
Jordan J, Grassi G. Natriuretic peptides in the cross-talk of human cardiovascular and metabolic regulation. J Hyperton 2015; 33(6): 1139-41.
[120]
Juliane SW, Daniel K, Markus L, et al. Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers. US20180291083 (2018)
[121]
Andrea M, Toni W, Anita W, Oliver S, Jens F, Harpreet S. Novel peptides, Combination of peptides as targets and for use in immunotherapy against gallbladder cancer and cholangiocarcinoma and other cancers. US20170342125 (2017)
[122]
Heiko S, Janet P, Kevin R, Philipp W, Rammensee HG. Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers. US20180222961 (2018)
[123]
Andrea M, Toni W, Colette S, Oliver S, Jens F, Harpreet S. Peptides, combination of peptides, and cell based medicaments for use in immunotherapy against urinary bladder cancer and other cancers. US20170253633 (2017)
[124]
Toni W, Jens F, Harpreet S, Andrea M, Martina O, Claudia W. Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers. US20180207251 (2018)
[125]
Schauer E, Baudys M, Varnum BC. Dental strip useful for delivering antimicrobial peptides, and reducing or preventing formation of dental caries disease in mammal e.g. human, comprises orally compatible backing layer, and delivery layer arranged on one surface of layer. WO2018191533 (2018)
Related Books
Frontiers in Clinical Drug Research - Anti-Cancer Agents
NEOPLASIA and FERTILITY
Breast Cancer: Current Trends in Molecular Research
The Evolution of Radionanotargeting towards Clinical Precision Oncology: A Festschrift in Honor of Kalevi Kairemo
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma
Topics in Anti-Cancer Research
Frontiers in Clinical Drug Research - Anti-Cancer Agents
Modern Cancer Therapies and Traditional Medicine: An Integrative Approach to Combat Cancers
Herbal Medicine: Back to the Future
Thrombosis in Cancer: A Medical Professional's Guide to Cancer Associated Thrombosis
Article Metrics
89
23